Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes

被引:0
作者
Christos Sambanis
Konstantinos Tziomalos
Evangelia Kountana
Nikitas Kakavas
Ioanna Zografou
Aikaterini Balaska
Georgios Koulas
Asterios Karagiannis
Chrysanthos Zamboulis
机构
[1] Aristotle University of Thessaloniki,Second Propedeutic Department of Internal Medicine
[2] Hippokration Hospital,undefined
来源
Acta Diabetologica | 2008年 / 45卷
关键词
Pioglitazone; Heart failure; Combination treatment; Type 2 diabetes; Brain natriuretic peptide;
D O I
暂无
中图分类号
学科分类号
摘要
We assessed the effect of the addition of pioglitazone on metabolic control and heart function of patients with type 2 diabetes already receiving sulfonylurea plus metformin. Forty-four patients were given 30 mg of pioglitazone for 3 months. Physical examination, laboratory tests including N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiography, were performed at baseline and at study completion. Target HbA1c levels were achieved by 44.2% of the patients. Pioglitazone ameliorated lipid profile and lowered liver enzymes and C-reactive protein. Significant increases in NT-proBNP by 39% (P < 0.005) were noticed, but echocardiographic parameters were not altered, even in high-risk subgroups (patients older than 60 years, with diabetes for more than 10 years, with hypertension, with elevated baseline NT-proBNP levels, with left ventricular hypertrophy). In patients with a greater than 60% increase in NT-proBNP levels, a significant increase in left ventricular ejection fraction (P < 0.05) and in fractional shortening (P < 0.05) was found. None of the patients developed edema or signs or symptoms of heart failure. Triple oral combination antidiabetic treatment is an effective therapeutic strategy and weight gain does not abrogate its beneficial actions. Pioglitazone does not affect heart function and even though it increases NT-proBNP, this appears to represent a reaction to volume overload.
引用
收藏
页码:23 / 30
页数:7
相关论文
共 177 条
  • [1] Gerich JE(2003)Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus Mayo Clin Proc 78 447-456
  • [2] Haffner SM(1999)Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study Diabetes Care 22 562-568
  • [3] D’Agostino R(2001)Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 S14-S21
  • [4] Mykkanen L(2001)Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 710-719
  • [5] Morrish NJ(2004)Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 256-263
  • [6] Wang S-L(2003)Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure J Am Coll Cardiol 41 1394-1398
  • [7] Stevens LK(1999)Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 2005-2012
  • [8] Fuller JH(2004)Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial Am J Med 116 223-229
  • [9] Keen H(2004)Improved glycemic control without weight gain using triple therapy in type 2 diabetes Diabetes Care 27 1577-1583
  • [10] Miyazaki Y(1972)Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 499-502